E-course: Theranostics in urological cancer: Where are we?
This e-course explains what theranostics is and explore its applications and potential in the treatment of prostate, bladder, and renal cancer.
| Organiser | European School of Urology (ESU) |
|---|---|
| CME | 1.00 |
| Duration | Approx. 60 minutes |
Precision medicine is rapidly evolving, and the role of imaging is increasingly becoming central in this regard. Theranostics is probably the most representative of this approach as PET radiotracers are used in identifying the targets and guiding the treatments. In urology, this type of treatment has been mostly studied in prostate cancer and currently indicated in the setting of most advanced stages of the disease.
This e-course provides the current overview and clinical experiences with theranostics in urological cancers focusing on future perspectives on hormone-sensitive prostate cancer, bladder cancer, and renal cancer.
Speakers:
- Prof. F. Sanguedolce (ES)
- Prof. Dr. D. Oprea-Lager (NL)
- Dr. L.M. Unterrainer (DE)
- Dr. J. Casuscelli (DE)
This e-course is brought to you in collaboration with the EAU Section Urological Imaging.